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Abstract
There is overwhelming evidence that persistent infection with high-risk human papillomaviruses
(HR-HPV) is the main risk factor for invasive cancer of the cervix. Due to this global public health
burden, two prophylactic HPV L1 virus-like particles (VLP) vaccines have been developed. While
these vaccines have demonstrated excellent type-specific prevention of infection by the
homologous vaccine types (high and low risk HPV types), no data have been reported on the
therapeutic effects in people already infected with the low-risk HPV type. In this study we explored
whether regression of CRPV-induced papillomas could be achieved following immunisation of out-
bred New Zealand White rabbits with CRPV VLPs. Rabbits immunised with CRPV VLPs had
papillomas that were significantly smaller compared to the negative control rabbit group (P ≤ 0.05).
This data demonstrates the therapeutic potential of PV VLPs in a well-understood animal model
with potential important implications for human therapeutic vaccination for low-risk HPVs.
Findings
Papillomaviruses (PVs) are small, non-enveloped viruses
containing a 8 kb double-stranded closed circular DNA
genome, encoding six early proteins (E1, E2, E4, E5, E6
and E7), two late proteins (L1 and L2) and a non-coding
regulatory region, the long-control region (LCR) [1]. The
LCR contains the origin of replication; early genes contrib-
ute to transformation and viral replication, and the late
genes provide capsid proteins [1]. There are over 100 dif-
ferent human PV (HPV) genotypes that have been fully
sequenced: the more important of these cause cervical,
vulva and vaginal cancers, genital warts and recurrent res-
piratory papillomatosis. HPVs can be divided into low-
risk, non-oncogenic or high-risk oncogenic types [2]
according to their ability to cause malignant disease [3].
The most prevalent low-risk types are HPV 6 and 11,
which cause 90% of genital warts (condyloma acumi-
nata), while HPV 16 and 18 are the predominant high-risk
types, causing 70% of cervical cancer and cervical intraep-
ithelial neoplasia (CIN) [2]. Cervical cancer is the second
most common cancer among women worldwide and the
most common in developing countries [4] contributing
significantly to a global public health burden.
In order to reduce the burden of HPV-induced infections,
many studies have investigated the efficacy of different
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prophylactic and therapeutic vaccines in various animal
models [5,6]. Preclinical studies using the cottontail rab-
bit papillomavirus (CRPV) in rabbits, canine oral papillo-
mavirus (COPV) in dogs and bovine papillomavirus
(BPV) in cattle have afforded a better understanding of the
molecular mechanism that regulate normal cell growth,
steps involved in cancerous cell changes [7] and have
examined the efficacy of several delivery systems [5,8-10].
These animal studies have demonstrated that the expres-
sion of PV L1 genes in a number of cell systems results in
the assembly of virus-like particles (VLPs), which elicit
high titers of virus-neutralizing serum antibodies when
administered as an immunogen [11,12]. As a result of the
successful animal preclinical trials, L1 VLPs were effec-
tively used as prophylactic vaccines in human clinical tri-
als. It was demonstrated that the HPV VLP (HPV 6, 11, 16
or 18) vaccine was 100% efficacious in preventing type-
specific precancerous lesions of the cervix, vulva, and
vagina and effective against genital warts [13-15]. Owing
to the promising human clinical trials, this prophylactic
quadrivalent HPV (types 6, 11, 16 and 18) L1 recom-
binant VLP vaccine (Gardasil) produced by Merck was
approved and registered by the Food and Drug Adminis-
tration (FDA) on the 8 June 2006. Furthermore, the sec-
ond preventative bivalent vaccine, Cervarix (produced by
GlaxoSmithKline), which contains HPV types 16/18 L1
VLPs has been approved for use in Australia and is under
review in other countries by various regulatory bodies.
However, while the current prophylactic vaccines would
be effective in preventing type-specific infection it is not
known whether these vaccines would afford protection to
women who are already infected with the non-oncogenic
HPV-associated disease. Recently, it was demonstrated
that women with existing oncogenic HPV DNA infection
did not benefit from HPV-16/18 L1 VLP vaccination [16].
Nevertheless, these prophylactic HPV VLP vaccines are
formulated with adjuvants and are able to elicit a strong
and robust immune response compared to the VLPs alone
[17]. Furthermore, the immune responses elicited by the
vaccine with adjuvant induced a T helper type 2 (TH2)-
like response with lasting immunity compared to the VLP
vaccine alone [17]. Therefore, this study used the CRPV
rabbit model system, to determine whether regression of
established CRPV-induced papillomas could be achieved
following the vaccination of rabbits with CRPV L1 VLP
vaccine, as a pilot investigation for further studies into the
use of low risk HPV VLP-based vaccines as a possible ther-
apeutic vaccine strategy.
A successful therapeutic vaccine should elicit a strong cell-
mediated immune response and induce lesion regression
in HPV established infection with no recurrence [18].
Indeed, studies have shown that HPV VLPs are able to
induce T-cell proliferative responses in different experi-
mental systems [19,20].
The CRPV L1 VLPs were produced in Spodoptera frugiperda
(Sf21) cells via recombinant baculovirus as previously
described [10]. Essentially, the CRPV L1 gene was direc-
tionally cloned into the pFastBac1 vector (Invitrogen),
transfected into DH10Bac-competent Escherichia coli cells
to generate bacmids which were then transfected into Sf21
cells (Invitrogen) according to the manufacturer's Bac-to-
Bac protocol. The infected Sf21 cells were pelleted, resus-
pended in PBS containing 0.4 g/ml CsCl and complete
protease inhibitor (Roche), and sonicated. The sonicated
suspension was centrifuged at 100,000 g at 10°C for 24 h.
Two distinct bands were observed on the CsCl gradient:
the top band was extracted by puncturing the tubes and
dialyzed against PBS (1.47 mM KH2PO4, 10
mMNa2HPO4, 2.7 mMKCl, 500 mMNaCl, pH 7.4) for 48
h. Dialyzed protein was divided into 100-l aliquots and
frozen at 70°C for further use.
As a negative control, the rotavirus VP 6 gene, Edim
(kindly provided by Dr M. Dennehy, Genbank accession
number DQ019612), cloned in BCG, was used and pre-
pared as previously described and designated pControl
[9].
All animal procedures were approved by the Research Eth-
ics Committee, Faculty of Health Sciences, University of
Cape Town, South Africa. A total of nine out-bred New
Zealand White rabbits (obtained from J.C rabbit Suppli-
ers, South Africa) were infected with infectious CRPV
(CRPVHershey strain) at 10-2 and 10-3 (2 sites per dilution
for each rabbit) as previously described [9]. The rabbits
were randomly divided into 2 groups, and the papilloma
sizes were measured 7 weeks post CRPV infection. All rab-
bits were immunised subcutaneously at week 8. Group 1
(n = 5) was immunized with CRPV L1 VLPs and group 2
(n = 4) was immunised with pControl 107 cfu/ml, as a
negative control. Each rabbit received 3 immunisations at
2 weekly intervals. Starting at week 7 post CRPV infection
the papilloma sizes were measured as length × width ×
height in millimetres and the geometric mean diameter
(GMD) was calculated for each papilloma every week. The
mean GMDs and the standard error of mean (SEM) for
each group was plotted against time for sites infected with
10-2 dilution of infectious CRPV. Data were compared
using the unpaired non-parametric, Mann-Whitney U-
test. Differences were considered significant at P ≤ 0.05.
The rabbits in each group were monitored weekly and
papilloma formation was measured each week post CRPV
infection. The geometric mean diameter (GMD) for the
10-2 dilution of virus (two sites per rabbit) was plotted
against time after immunisation with CRPV VLPs andVirology Journal 2008, 5:45 http://www.virologyj.com/content/5/1/45
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pControl (Fig. 1). The regression rate of the papillomas at
every site for each experimental rabbit group was tabu-
lated in Table 1. The rabbits immunised with pControl
demonstrated no papilloma regression even after the third
immunisation and the papillomas grew progressively.
Similar progressive papilloma growths were observed in
rabbits injected with PBS (pH 7.0) (data not shown). In
contrast, the rabbits immunised with CRPV VLPs had pap-
illomas that grew slower after each immunisation and
were significantly smaller compared to the control group
(P ≤ 0.05) (Fig. 1). In addition, rabbits immunised with
CRPV VLPs had papillomas that regressed to a GMD < 5
mm (15 of 20 sites; 75%) (Table 1) compared to no pap-
illoma reduction in the control group.
The results produced in this study show that immunisa-
tion with CRPV L1 VLPs is able to elicit a significant ther-
apeutic effect in rabbits with existing CRPV induced
papillomas. This is a novel result, which at first sight has
significant implications for therapeutic human vaccina-
tion, given the close correspondence of the animal model
to human wart pathology. However, the literature is
replete with studies that show that HPV L1 VLPs generate
mainly humoral responses against type-specific HPVs,
and they are only effective in prophylaxis without afford-
ing a therapeutic effect against oncogenic HPV-induced
infections [16,21].
The rationale for this is that the HPV life-cycle is totally
intraepithelial and the virus requires a differentiated squa-
mous epithelium to complete its life cycle and produce
infectious viral particles [22]. Furthermore, in late gene
expression the viral DNA is often integrated and the L1
gene would probably be disrupted. Thus the levels of L1
expression in cytotoxic T cell-accessible cells would be
presumed to be undetectable, possibly preventing a L1-
specific CTL response [23]. However, in a study by Zhang
et al., [24] it was shown that patients with established gen-
ital warts were able to induce frequent regression when
vaccinated with HPV 6b VLPs, compared to the historical
Regression of papillomas on the backs of rabbits (NZW) following vaccination with CRPV VLPs Figure 1
Regression of papillomas on the backs of rabbits (NZW) following vaccination with CRPV VLPs. A total of nine 
rabbits were challenged with 10-fold dilutions of infectious CRPV (10-fold dilution two sites per dilution). The rabbits were 
divided into two groups and immunized 3 times at 2 week intervals (↑) with CRPV VLPs(n = 5), or pControl (n = 4) antigen. 
The appearance of papillomas was monitored, the papilloma sizes were measured weekly beginning at week seven and the 
GMDs calculated. The mean GMDs and SEM of papillomas were plotted against time for the sites challenged with 10-2 dilution 
of infectious CRPV. *P ≤ 0.05 (Mann-Whitney U-test).
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controls [24]. Furthermore, comparable results were
observed in a placebo-controlled human clinical trial:
where women with pre-existing transient HPV 16 infec-
tion were vaccinated with HPV 16 L1 VLPs, complete pro-
tection was achieved 91.2% (95% CI, 80–97) [13]. It is
suggested that the aforementioned results could be due to
the secondary effects on the adjacent cells and tissues trig-
gered by immune recognition of a primary target, also
called a bystander effect [23]. Thus the levels of L1 would
indeed be detected by the immune system but would be
below the experimental (such as western blot or immun-
ofluorescence) detection levels and would therefore be
unrecognised [25,26].
Interestingly, the findings presented in the current study
are in agreement with those mentioned above and we
believe that the therapeutic effect afforded by CRPV L1
VLP is true. In deed, the CRPV VLP vaccine results pre-
sented here and the published commercial oncogenic
HPV VLP vaccines have generated disparate results. One
possible explanation for the differences observed in the
CRPV model and the human trials is the route of immu-
nisation, which could induce different immune pathways
rendering different degrees of papilloma regression. Fur-
thermore, the incidence of virus induction is dose
dependant [27] and would certainly afford different pap-
illoma regression in a natural and experimental study. In
addition, although spontaneous regression of CRPV-
induced papillomas have been reported to occur in less
than 10% of infected rabbits [27] this was not observed in
our study. The data shows that rabbits with existing CRPV-
induced papillomas induced significant (P ≤ 0.05) papil-
loma regression following vaccination with CRPV L1 VLPs
compared to the control group which grew papillomas
progressively. Thus, the results of this pilot study are sur-
prisingly encouraging as it demonstrates for the first time
in a controlled based robust animal model the therapeutic
potential of the CRPV L1 VLP vaccines.
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